J&J response in Guidant bidding war likely soon, analysts say | VailDaily.com
YOUR AD HERE »

J&J response in Guidant bidding war likely soon, analysts say

TRENTON, N.J. – With a deadline of Tuesday night looming for Johnson & Johnson to raise its bid or let rival Boston Scientific acquire coveted heart device maker Guidant Corp., many analysts were expecting a J&J move before the stock market opens Tuesday.That’s because the diversified health care company is to report fourth-quarter and 2005 year-end earnings at a Tuesday morning meeting likely to be packed with analysts.”It’s already getting down to the 11th hour,” said CIBC World Markets analyst John Calcagnini. “If I had to bet one way or the other, I would bet that they’re going to raise their bid.”Natick, Mass.-based Boston Scientific Corp. is offering about $27.2 billion, or $80 per share for Indianapolis-based Guidant, whose board last Tuesday declared that bid superior to J&J’s last offer: $24.2 billion, or $71 per share. New Brunswick-based J&J has until Tuesday night to make a counteroffer; Guidant’s board has until Wednesday to accept Boston Scientific’s offer.J&J spokesman Marc Monseau declined comment Monday.Despite a rash of lawsuits and regulatory investigations since Guidant began issuing warnings and recalls for nearly 300,000 pacemakers and heart defibrillators in June, Boston Scientific last month started a bidding war for Guidant.Independent pharmaceuticals analyst Hemant Shah of HKS & Co. said he could not recall Johnson & Johnson ever getting into a bidding war before or even failing to complete a planned acquisition.”J&J’s a pretty disciplined company,” he said.Pacemakers and implantable defibrillators are seen as a crucial new market by J&J and Boston Scientific. The market is projected to grow 15 percent per year, fueled by aging baby boomers and evidence the devices can help more types of heart patients. Guidant could have a new drug-coated stent ready for U.S. sales late next year, and J&J and Boston Scientific compete fiercely in stents, which keep arteries open after blockages are cleared.Shah said J&J needs Guidant because very few companies have such products or infrastructure, and they don’t face competition from generic products after several years, as medicines do.In trading Monday afternoon on the New York Stock Exchange, J&J shares rose 13 cents to $60.93; Boston Scientific shares fell 20 cents to $23.39 and Guidant shares rose 20 cents to $76.15, nearing their 52-week high.—On the Net:Johnson & Johnson: http://www.jnj.comGuidant: http://www.guidant.comBoston Scientific: http://www.bostonscientific.com


Support Local Journalism


Start a dialogue, stay on topic and be civil.
If you don't follow the rules, your comment may be deleted.

User Legend: iconModerator iconTrusted User